Cure8 news brief
Phase III AFFIRM results suggest a subcutaneous risankizumab regimen may increase endoscopic remission in Crohn’s disease, which matters for patients and clinicians weighing biologic options and for regulatory approval decisions that could change access and dosing convenience.
The piece also highlights competition in the IL‑23 inhibitor space (guselkumab) and an ongoing head‑to‑head trial that could affect future treatment choices.
Adult patients with moderately to severely active Crohn’s disease, especially those considering or currently on biologic/IL‑23 therapies; gastroenterologists and IBD clinicians; clinical researchers following biologic trials and regulatory developments.
This AllSci story summarizes
Article is a news summary of conference‑presented Phase III data and regulatory filings. It reports remission percentages but omits p‑values, confidence intervals, full randomized population denominators, and numerical safety event rates. For treatment decisions, seek the full trial publication, regulatory documents, or discuss with a clinician.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This Phase 3 trial directly compares two IL-23–targeting biologic therapies in moderate-to-severe Crohn's disease with a 52-week deep remission endpoint, which could inform future treatment choices if results are...
Researchers are testing whether targeting fungi with fluconazole can boost how well IL-23 biologics work for Crohn’s disease — if positive, this could point to a new adjunctive strategy to improve responses to biologic...
An FDA approval means another biologic option is available for Crohn’s disease, which could affect treatment choices and insurance coverage. The approval also signals pharma competition and pipeline activity that may...
